These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 2538227)
21. Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. Reuveni D; Halperin D; Shalit I; Priel E; Fabian I Biochem Pharmacol; 2008 Mar; 75(6):1272-81. PubMed ID: 18191106 [TBL] [Abstract][Full Text] [Related]
22. Camptothecin: current perspectives. Thomas CJ; Rahier NJ; Hecht SM Bioorg Med Chem; 2004 Apr; 12(7):1585-604. PubMed ID: 15028252 [TBL] [Abstract][Full Text] [Related]
23. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631 [TBL] [Abstract][Full Text] [Related]
24. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542 [TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757 [TBL] [Abstract][Full Text] [Related]
26. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Poddevin B; Riou JF; Lavelle F; Pommier Y Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227 [TBL] [Abstract][Full Text] [Related]
27. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981 [TBL] [Abstract][Full Text] [Related]
28. Synthesis and cytotoxic activity of substituted 7-aryliminomethyl derivatives of camptothecin. Dallavalle S; Merlini L; Morini G; Musso L; Penco S; Beretta GL; Tinelli S; Zunino F Eur J Med Chem; 2004 Jun; 39(6):507-13. PubMed ID: 15183909 [TBL] [Abstract][Full Text] [Related]
29. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. Liu LF; D'Arpa P Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311 [No Abstract] [Full Text] [Related]
30. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne. Wang LK; Rogers BD; Hecht SM Chem Res Toxicol; 1996; 9(1):75-83. PubMed ID: 8924619 [TBL] [Abstract][Full Text] [Related]
31. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Labourier E; Riou JF; Prudhomme M; Carrasco C; Bailly C; Tazi J Cancer Res; 1999 Jan; 59(1):52-5. PubMed ID: 9892183 [TBL] [Abstract][Full Text] [Related]
32. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102 [TBL] [Abstract][Full Text] [Related]
33. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151 [TBL] [Abstract][Full Text] [Related]
35. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro. Zhao R; al-Said NH; Sternbach DL; Lown JW J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520 [TBL] [Abstract][Full Text] [Related]
36. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Benedetti P; Fiorani P; Capuani L; Wang JC Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982 [TBL] [Abstract][Full Text] [Related]
37. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity. Poot M; Hiller KH; Heimpel S; Hoehn H Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696 [TBL] [Abstract][Full Text] [Related]
38. Role of flexibility and long range communication on the function of human topoisomerase I. Chillemi G; Fiorani P; Bruselles A; Castelli S; Campagna A; Sarra O; Tesauro C; Fiorentini M; Vassallo O; D'Annessa I; Santoleri S; Desideri A Ital J Biochem; 2007 Jun; 56(2):110-4. PubMed ID: 17722651 [TBL] [Abstract][Full Text] [Related]
39. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Mattern MR; Mong SM; Bartus HF; Mirabelli CK; Crooke ST; Johnson RK Cancer Res; 1987 Apr; 47(7):1793-8. PubMed ID: 3028614 [TBL] [Abstract][Full Text] [Related]
40. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors. Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M Bioorg Med Chem Lett; 2004 Jul; 14(14):3659-63. PubMed ID: 15203138 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]